
Clark of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515

ř.

Secretary of the Senate Office of Public Records 232 Hart Building Washington, EC 20510



01 FEB 14 PM 1: 26

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

Registrant Name     Parry and Romant Associates, Inc.	
Registrant Address	DC 26002 USA
Principal Place of Business (if different from line 2)	
City State/Exp (or Country)	
Edward Baxter 202-547-4980	uil (optional) 5. Sonate ED # 30792-428
Client Name  Seif  Pfizer, Inc.	5. House ID # 30115020
Check if this filing amends a previously filed version of the Check if this is a Termination Report   NCOME OR EXPENSES - Complete Eithe	n Date tl. No Lobbying Activity:
12. Lobbying Firms	13. Organizations
NCOME relating to lobbying activities for this reporting eriod was:	EXPENSES relating to lobbying activities for this reporting period were:
ess than \$10,000 📋	Less than \$10,000 🗆
0,000 or more $ >>                                 $	\$10,000 or more >> \$ Expenses (nearest \$20,000)  14. REPORTING METHOD. Check box to indicate expense
ovide a good faith estimate, rounded to the nearest 10,000 of all lobbying related income from the client actuding all payments to the registrant by any other entity of tobbying activities on behalf of the client).	accounting method. See instructions for description of options.  Method A. Reporting amounts using LDA definitions only
, , , , , , , , , , , , , , , , , , ,	Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code
	☐ Method C. Reporting amounts under section 162(e) of the internal Revenue Code
nature "	Date 02/13/2001

Registrant Name:	Parry and Romani Associates, Inc.		
Client Name:	Pfizer, Inc.		
engaged in tobbyi	TIVITY. Select as many codes as necess ag on behalf of the client during the repo uested. Attach additional page(s) as nece	sary to reflect the general issue areas in which the registrant oring period. Using a separate page for each code, provided.	ė
	e area code <u>CPT</u> (one per pag	(e)	
16. Specific Lob H.R. 434, Ai protection fo	bying issues Irican Growth & Opportunity Act., Op or U.S. pharmaceuticuls abroad.	spose provision in section 116 that undermines intellect	ial property
17. House(s) of C Department House of Rep Senate	Congress and Federal agencies contacted of Commerce: Patent and Trademark presentatives	□ Check if None Office	
18. Name of each	individual who acted as a lobbyist in thi	is issue area  Covered Official Position (if applicable)	New
Baxter, Edwa	erd		<b>B</b> r.
Davis, Shann	ол		No l
DeConcini, D			No
Martin, Jack			No No
Parry, Thomas			No
	······································		No
Romani, Rom	· · · · · · · · · · · · · · · · · · ·		No.
Składany, Liz	102		No
	a foreign entity in the specific issues liste		
		Date 02/13/2001	
Printed Name and T	itle Romano Romani - President	Pa	ge 2 of 7

Client Name: Pfizer, Inc.  LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant orgaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.  15. General issue area code: HCR. (one per page)  16. Specific Lobbying issues:  "Urge FDA to establish standards to review applications for approval of injectable bioequivalents.  "HR. 4461: oppose provisions to bring usuafe and ineffective pharmaceuticals into the U.S.  17. House(s) of Congress and Federal agencies contacted House of Representatives  Name Covered Official Position (if applicable) New NONE, No.  NONE, No.  No.  No.  19. Interest of each foreign entity in the specific issues listed on line 16 above X Check if None  Signature Date 27(13/2001)  Page 42/13/2001	LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.  15. General issue area code	Registrant Name:	Parry and Romani Associates, Inc.		
engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.  15. General issue area code.   #CR	engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.  15. General issue area code   MCR   (one per page) 16. Specific Lobbying issues *Urge FDA to establish standards to review applications for approval of injectable bioequivalents.  ***B.R. 4461: oppose provisions to bring unsafe and ineffective pharmaceuticals into the U.S.  17. House(s) of Congress and Federal agencies contacted   Check if None   House of Representatives    18. Name of each individual who acted as a lobbyist in this issue area  Name   Covered Official Position (if applicable)   New    NONE.   No  9. Interest of each foreign entity in the specific issues listed on line 16 above   X   Check if None    Interest of each foreign entity in the specific issues listed on line 16 above   X   Check if None    Date   02/13/2001	Client Name:	Pfizer, Inc.		_
16. Specific Lobbying issues  **Urge FDA to establish standards to review applications for approval of injectable bioequivalents.  **H.R. 4461: oppose provisions to bring unsafe and ineffective pharmaceuticals into the U.S.  17. House(s) of Congress and Federal agencies contacted House of Representatives  Senate  18. Name of each individual who acted as a lobbyist in this issue area  Name  Covered Official Position (if applicable)  None.  No  Interest of each foreign entity in the specific issues listed on line 16 above  Check if None  Date 02/1J/2001	16. Specific Lobbying issues  **Urge FDA to establish standards to review applications for approval of injectable bioequivalents.  **H.R. 4461: oppose provisions to bring unsafe and ineffective pharmaceuticals into the U.S.  17. House(s) of Congress and Federal agencies contacted House of Representatives  Senate  18. Name of each individual who acted as a lobbyist in this issue area  Name    Covered Official Position (if applicable)   New	engaged in lobbyi	ng on behalf of the client during the report	ting period. Using a separate page for each code, pro	tunt vide
**Urge FDA to establish standards to review applications for approval of injectable bioequivalents.  **H.R. 4461: oppose provisions to bring unsafe and ineffective pharmaceuticals into the U.S.  17. House(s) of Congress and Federal agencies contacted House of Representatives  Senate  18. Name of each individual who acted as a lobbyist in this issue area  Name Covered Official Position (if applicable) New  NONE, No  19. Interest of each foreign entity in the specific issues listed on line 16 above	**Urge FDA to establish standards to review applications for approval of injectable bioequivalents.  **H.R. 4461: oppose provisions to bring unsafe and ineffective pharmaceuticals into the U.S.  17. House(s) of Congress and Federal agencies contacted House of Representatives  Senate  18. Name of each individual who acted as a lobbyist in this issue area  Name Covered Official Position (if applicable) New  NONE, No  19. Interest of each foreign entity in the specific issues listed on line 16 above X Check if None  Ignature Date 92/13/2001	15. General issue	area code <u>HCR</u> (one per page	)	
17. House(s) of Congress and Federal agencies contacted House of Representatives Senate  18. Name of each individual who acted as a lobbyist in this issue area  Name  Covered Official Position (if applicable)  New  NONE.  No  Po  Interest of each foreign entity in the specific issues listed on line 16 above  Mean the specific issues listed on line 16 above  Mean the specific issues listed on line 16 above  Mean the specific issues listed on line 16 above  Mean the specific issues listed on line 16 above  Mean the specific issues listed on line 16 above  Mean the specific issues listed on line 16 above  None	17. House(s) of Congress and Federal agencies contacted Bouse of Representatives  Senate  18. Name of each individual who acted as a lobbyist in this issue area  Name Covered Official Position (if applicable) New  NONE. No  9. Interest of each foreign entity in the specific issues listed on line 16 above Check if None	<ol> <li>Specific Lob</li> <li>*Urge FDA</li> </ol>	bying issues to establish standards to review applica	tions for approval of injectable bioequivalents.	
House of Representatives    Senate	House of Representatives Senate  18. Name of each individual who acted as a lobbyist in this issue area  Name   Covered Official Position (if applicable)   New  NONE,   No	**H.R. 4461	: oppose provisions to bring unsufe and	inessective pharmaceuticals into the U.S.	
Senate  18. Name of each individual who acted as a lobbyist in this issue area  Name   Covered Official Position (if applicable)   New    NONE,   No    No	Senate	17. House(s) of (	Congress and Federal agencies contacted	○ Check if None	
Name  Covered Official Position (if applicable)  No  No  No  Interest of each foreign entity in the specific issues listed on line 16 above  Date 02/13/2001	Name   Covered Official Position (if applicable)   New NONE,   No   No   No   No   No   No   No   N		resentutives		
19. Interest of each foreign entity in the specific issues listed on line 16 above   Check if None  Date 92/13/2001	9. Interest of each foreign entity in the specific issues listed on line 16 above   Check if None  Date 92/13/2001		individual who acted as a lobbyist in this		New
ignature Date <u>02/13/2001</u>	ignature Date <u>02/13/2001</u>	NONE,		7.	No
ignature Date 02/13/2001	ignature Date <u>02/13/2001</u>		···		
gnature Date 02/13/2001	gnature Date 02/13/2001		¬		
ignature Date 02/13/2001	ignature Date <u>02/13/2001</u>				``
ignature Date 02/13/2001	ignature Date <u>02/13/2001</u>				
ignature Date 02/13/2001	ignature Date <u>02/13/2001</u>				
ignature Date 02/13/2001	ignature Date <u>02/13/2001</u>	·	······································		
ignature Date 02/13/2001	ignature Date <u>02/13/2001</u>	**************************************			
Signature Date <u>02/13/2001</u>	ignature Date <u>02/13/2001</u>		ì		
		9. Interest of eac	t foreign entity in the specific issues listed	on line 16 above 🛮 🗷 Check if None	
		iignature		Date 02/13/2001	
	rage 3 of 7				Dane 1 11 =

Client Name: Pfizer, Inc.	<u>c.</u>	
SPER MAINE.		
LOBBYING ACTIVITY. Select as many codes as nec engaged in lobbying on behalf of the client during the re nformation as requested. Attach additional page(s) as n	ressary to reflect the general issue areas in which the registrant eporting period. Using a separate page for each code, provide eeded.	
15. General issue area code <u>MED</u> (one per p	page)	
<ol> <li>Specific Lobbying issues</li> <li>Various legislative efforts to enact a medicare p.</li> </ol>	rescription drug henefit.	
•	•	
•	•	
<ol> <li>House(s) of Congress and Federal agencies contact House of Representatives</li> </ol>	ced	
Senate		
8. Name of each individual who acted as a lobbyist in	this issue area	
Name	Covered Official Position (if applicable)	New
Baxter, Edward		No
Davis, Shannon		No
DeConcini, Dennis	11 11 11 11 11 11 11 11 11 11 11 11 11	No
Hatch, Scott		No
Hatch, Scott Martin, Jack		No No
		No
Martin, Jack		!

Registrant Name: Parry and Romani Associates, Inc. Client Name: Pfizer, Inc. Data Hem Description 18a 18b 18c Lubbyist Name Covered Official Position New Lobbyist Remani, Romano No Lobbyist Name Covered Official Position New Lebbyist 18a Skladany, Linda 186 180 No

Page 5 of 7

Registrant Name:	Parry and Romani Asso	ciates, Inc.	4. 1	
lient Name:	Pfizer, Inc.			
ngaged in lobbyi	TIVITY. Select as many co- ing on behalf of the client du juested. Attach additional pa	wing the reporting period. Using	neral issue areas in which the regis a separate page for each code, pr	revide
<ol> <li>General issu</li> <li>Specific Lot 000., No Ac</li> </ol>		(one per page)		
	·			
7. House(s) of	Congress and Federal agenci	es contacted	★ Check if None	
	•			
l. Name of each	1 individual who acted as a h	obbyist in this issue area		
3. Name of each	1 individual who acted as a h	·	ial Position (if applicable)	New
	ı individual who acted as a h	·	ial Position (if applicable)	New No
Name	ı individual who acted as a h	·	ial Position (if applicable)	~~
Name	n individual who acted as a h	·	ial Position (if applicable)	~~
Name	n individual who acted as a h	·	ial Position (if applicable)	~~
Name	n individual who acted as a h	·	ial Position (if applicable)	~~
Name	n individual who acted as a le	·	ial Position (if applicable)	~~
Name	n individual who acted as a to	·	ial Position (if applicable)	~~
Name	n individual who acted as a lo	·	ial Position (if applicable)	~~
Name	n individual who acted as a to	·	ial Position (if applicable)	~~
Name NONE,		·	ial Position (if applicable)  **Check if None	~~
Name NONE,		Covered Office		~~
Name NONE,	h foreign entity in the specif	Covered Office	₩ Check if None	~~
Name  NONE,  Interest of each	th foreign entity in the specif	Covered Office	₩ Check if None	No.

Registrant Name:	Parry and Romani Associates, Inc.		
Client Name:	Pfizer, Inc.		
engaged in lobbyis	FIVITY. Select as many codes as necessary to a ag on behalf of the client during the reporting po- nested. Attach additional page(s) as needed.	effect the general issue areas in which the registrant eriod. Using a separate page for each code, provide	
16. Specific Lobi	area code <u>TAX</u> (one per page) sying issues wity this recording period.,		
17. House(s) of C	ongress and Federal agencies contacted	▼ Check if None	
18. Name of each	individual who acted as a lobbyist in this issue	. area	
Name		overed Official Position (if applicable)	New
Name NONE,			New No
·····	C	overed Official Position (if applicable)	
·····	C		
NONE,	C	overed Official Position (if applicable)	